COMMUNIQUÉS West-GlobeNewswire

Atara Biotherapeutics Announces Third Quarter 2018 Financial Results and Recent Operational Progress
06/11/2018
SOUTH SAN FRANCISCO, Calif., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with [...]
Kura Oncology to Participate in Two Upcoming Investor Conferences
06/11/2018
SAN DIEGO, Nov. 06, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that Troy [...]
OpGen Completes Specimen Accrual and Testing in Acuitas® Clinical Verification Study
06/11/2018
Study evaluated potential utility in management of complicated urinary tract infections; Analysis and peer-reviewed manuscript preparation are underway GAITHERSBURG, Md., Nov. 06, 2018 (GLOBE NEWSWIRE) -- OpGen, Inc. ( [...]
Spark Therapeutics Reports Third Quarter 2018 Financial Results and Recent Business Progress
06/11/2018
PHILADELPHIA, Nov. 06, 2018 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ: ONCE), a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, announced today [...]
Otonomy Presents Data Highlighting Potential of OTO-413, an Otic Sustained-Exposure Formulation of BDNF, to Treat Hearing Loss
06/11/2018
Society for Neuroscience Features OTO-413 Presentation as Neuroscience 2018 Hot Topic SAN DIEGO, Nov. 06, 2018 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development [...]
Vericel Reports Record Third Quarter Revenues of $22.5 Million and Raises Full Year 2018 Revenue Guidance
06/11/2018
58% Revenue Growth Over Third Quarter 2017 Conference Call Today at 8:30am Eastern Time CAMBRIDGE, Mass., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the [...]
Adaptimmune Reports Third Quarter 2018 Financial Results and Business Update
06/11/2018
Progressed to expansion phase for MAGE-A10 triple tumor and MAGE-A4 basket studies after favorable safety review of Cohort 3 data with target doses of 5 billion cells Continued dosing in Cohort 1 of AFP study, with [...]
Veteran Oncology Biotechnology Executive and Third Rock Ventures Entrepreneur in Residence Markus Warmuth, MD, Joins IMV Inc. Board of Directors
06/11/2018
DARTMOUTH, Nova Scotia, Nov. 06, 2018 (GLOBE NEWSWIRE) -- IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology corporation, today announced that it has appointed seasoned biopharmaceutical executive Markus [...]
AxoGen to Host Third Annual Analyst and Investor Day on November 19, 2018
06/11/2018
ALACHUA, Fla., Nov. 06, 2018 (GLOBE NEWSWIRE) -- AxoGen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, today announced [...]
Cyclacel Pharmaceuticals to Release Third Quarter 2018 Financial Results
06/11/2018
BERKELEY HEIGHTS, N.J., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC, Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on [...]
Microbix Exhibiting at MEDICA Trade Fair
06/11/2018
Showcasing Antigen and Quality Assessment Products TORONTO, Nov. 06, 2018 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, Microbix ® ), an innovator of biological products and technologies, announces that it [...]
G1 Therapeutics to Present at Investor Conferences in November 2018
06/11/2018
RESEARCH TRIANGLE PARK, N.C., Nov. 06, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that Chief Executive Officer Mark Velleca, M.D., Ph.D., will [...]
Lexicon Pharmaceuticals to Present at Upcoming Investor Conference
06/11/2018
THE WOODLANDS, Texas, Nov. 06, 2018 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Jeffrey L. Wade, J.D., Executive Vice President, Corporate and Administrative Affairs and Chief [...]
Akcea Therapeutics to Present at Upcoming Investor Conferences
06/11/2018
BOSTON, Nov. 06, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing drugs to treat patients with serious and rare [...]
InspireMD Announces Third Quarter 2018 Financial Results and Provides Corporate Update
06/11/2018
Presented Three-Year Data Highlighting Long-Term Safety and Efficacy of CGuard™ Embolic Prevention System On-Track to Submit U.S. IDE in Mid-2019 Company to Host Investor Conference Call at 8:00am ET TEL AVIV, Israel, [...]
RedHill Biopharma to Host Third Quarter 2018 Financial Results Conference Call on November 13, 2018
06/11/2018
TEL-AVIV, Israel and RALEIGH, N.C., Nov. 06, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily [...]
Capricor Therapeutics to Present Third Quarter Financial Results and Corporate Update on November 13
06/11/2018
LOS ANGELES, Nov. 06, 2018 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment of [...]
Nabriva Therapeutics Reports Third Quarter 2018 Financial Results and Recent Corporate Highlights
06/11/2018
- New Drug Application for CONTEPO ™ submitted to FDA in October 2018 - - Company preparing for potential commercialization of two, first-in-class antibiotics, Lefamulin (IV and Oral) and CONTEPO (IV) in the United [...]
Tonix Pharmaceuticals Presented Results and Retrospective Analyses of Phase 3 P301 “HONOR” Study in Poster Presentation at CNS Summit 2018
06/11/2018
Retrospective Analysis Revealed Clinically Meaningful Response to Tonmya® in Female PTSD Participants Overall and for Non-Combat-Related Traumas Experienced Within Nine Years Prior to Screening Results from Phase 3 P301 [...]

Pages